Dr. Marie Hudson

My research program has two axes: (1) systemic autoimmune rheumatic diseases, and (2) immune-related adverse events (irAE) secondary to cancer immunotherapies.

1) Systemic autoimmune rheumatic diseases

I am particularly interested in systemic sclerosis and autoimmune myositis. I have recently developed an interest in cellular therapies for autoimmune diseases, including autologous hematopoietic stem cell transplant and mesenchymal stromal cells. I am also interested in translational projects in scleromyositis and epigenetic signatures of disease.

2) Immune-related adverse events (irAE) secondary to cancer immunotherapies

Most recently, I have developed an interest in immune-related adverse events (irAE) secondary to cancer immunotherapies as a “human” model for classical autoimmune diseases. Specifically, we are trying to identify predictive biomarkers, mechanisms of irAE and mitigation strategies in order to optimize the use of immunotherapies and improve outcomes of cancer patients.